Rabbit polyclonal to SUMO1/SUMO-1
ELISA, WB, IP
Human SUMO1 / SUMO-1
DAP1 antibody; GMP1 antibody; PIC1 antibody; SMT3 antibody; UBL1 antibody; OFC10 antibody; SENP2 antibody; SMT3C antibody; SMT3H3 antibody; GMP1 antibody; PIC1 antibody; SMT3 antibody; Ubl1 antibody; SMTP3 antibody; Smt3C antibody; SMT3H3 antibody; SUMO-1 antibody; SENTRIN antibody; DAP1 antibody; GMP1 antibody; OFC10 antibody; GMP1 antibody; PIC1 antibody; PIC1 antibody; SENP2 antibody; MGC103203 antibody; SENTRIN antibody; SMT3 antibody; SMT3C antibody; Smt3C antibody; SMT3H3 antibody; SMT3H3 antibody; SMTP3 antibody; Sumo1 antibody; SUMO-1 antibody; Ubl1 antibody; UBL1 antibody; OK/SW-cl.43 antibody; SMT3 antibody; SUMO1 antibody; SUMO-1 antibody
Produced in rabbits immunized with purified, recombinant Human SUMO1 / SUMO-1 (rh SUMO1 / SUMO-1; AAH66306.1; Ser 2-Val 101). SUMO1 / SUMO-1 specific IgG was purified by Human SUMO1 / SUMO-1 affinity chromatography.
0.2 μm filtered solution in PBS with 5% trehalose
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
WB: 0.5-1 μg/mL
ELISA: 0.1-0.2 μg/mL
This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human SUMO1. The detection limit for Human SUMO1 is approximately 0.00975 ng/well.
IP: 1-4 μg/mg of lysate
SUMO1 / SUMO-1 Antibody, Rabbit PAb, Antigen Affinity Purified, Western blot
SUMO1 / SUMO-1 Antibody, Rabbit PAb, Antigen Affinity Purified
Small ubiquitin-like modifier protein (SUMO) modification is a highly dynamic process, catalyzed by SUMO-specific activating (E1), conjugating (E2) and ligating (E3) enzymes, and reversed by a family of SUMO-specific proteases (SENPs). Small ubiquitin-like modifier 1 (SUMO1) is a member of the superfamily of ubiquitin-like proteins. Despite its structural similarity with ubiquitin, SUMO1 does not seem to play any role in protein degradation. SUMO1 plays an important role in modulation of NOX activity required for ROS generation. SUMO1 haploinsufficiency results in cleft lip and palate in animal models. SUMO1 gene variation in human non-syndromic cleft lip with or without cleft palate (NSCLP) development. SUMO-1 may be useful as a novel target for therapy in oral squamous cell carcinoma (SCC) as well as a clinical indicator for tumor recurrence together with Mdm2.
- Kim HJ, et al. (2011) SUMO1 attenuates stress-induced ROS generation by inhibiting NADPH oxidase 2. Biochem Biophys Res Commun. 410(3): 555-62.
- Zuo Y, et al. (2009) Small ubiquitin-like modifier protein-specific protease 1 and prostate cancer. Asian J Androl. 11(1): 36-8.
- Song T, et al. (2008) SUMO1 polymorphisms are associated with non-syndromic cleft lip with or without cleft palate. Biochem Biophys Res Commun. 377(4): 1265-8.
- Katayama A, et al. (2007) Overexpression of small ubiquitin-related modifier-1 and sumoylated Mdm2 in oral squamous cell carcinoma: possible involvement in tumor proliferation and prognosis. Int J Oncol. 31(3): 517-24.
Related Products / Services
- Human SUMO1/SUMO-1 (His Tag) recombinant protein
- Human SUMO1 Recombinant protein (GST tag)
- Human SUMO1/SMT3C/SMT3H3/UBL1 (His tag) recombinant protein
- Human SUMO1 Recombinant protein (6*His tag)
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"